By OBBM Network Editorial Staff

Ann Vandersteel

When reports of long‑COVID sufferers still producing spike protein surfaced, the administration faced a stark dilemma: how to protect a vulnerable elderly population while restoring confidence in the nation’s medical supply chain.

Re‑examining the Vaccine Fallout

Guests on the program argued that the COVID‑19 mRNA shots functioned more like a bioweapon than a vaccine, citing laboratory studies that showed persistent messenger RNA lingering in cells for years. One expert explained, “We’re going on three years now with one guy I know, and he’s still making spike protein. No shut‑off valve in the future.” The lingering presence of the spike protein, they warned, could trigger chronic inflammation and other health issues.

The discussion highlighted the need for transparent data and independent expert panels, a request President Trump made after hearing concerns from his advisors. The goal, according to the guests, is to ensure any future emergency medical products undergo rigorous, reproducible testing before public deployment.

Strengthening Domestic Drug Production

With the elderly population described as “very vulnerable” due to reliance on multiple prescription drugs, the guests stressed that any disruption in the drug supply chain would be catastrophic. They praised the administration’s push to bring pharmaceutical manufacturing back to the United States, framing it as a corrective measure against the “Biden years” when, they claimed, drug companies captured regulatory agencies.

Patricia Cavazzone’s tenure at the Center for Drug Evaluation and Research (CDER) was cited as an example of how agency capture can undermine public health. The guests argued that restoring agency independence is essential for safeguarding drug safety and efficacy.

The Role of ASPR, BARDA, and the National Disaster Medical System

Matt Buckham, a White House liaison to the Department of Health and Human Services, described his assignment as a Schedule C advisor to the Administration for Strategic Preparedness and Response (ASPR). He explained that ASPR coordinates the National Disaster Medical System, urgent manufacturing, and the Biomedical Advanced Research and Development Authority (BARDA) to respond to pandemics and other biological threats.

John Knox, a veteran of disaster response ranging from forest fires to floods, was highlighted for his hands‑on experience. Buckham noted that Knox’s background helped shape a “plan” to address both vaccine injury claims and emerging threats like the New World Screw Worms that jeopardized the cattle industry.

Scientific Advances and Future Safeguards

The conversation turned to cutting‑edge molecular biology, noting that modern sequencing can now capture a complete snapshot of gene activity in individual cells. This technology, they argued, could identify aberrant gene expression caused by lingering vaccine mRNA, providing a diagnostic tool for long‑COVID patients.

Guests warned that without a built‑in “off switch,” mRNA‑based therapies risk uncontrolled protein production. They called for stricter regulatory oversight and transparent reporting to prevent repeat scenarios.

Looking Ahead

Overall, the interview painted a picture of an administration determined to learn from past missteps, rebuild domestic capabilities, and enforce scientific rigor in emergency medical responses. By aligning federal agencies, industry, and independent experts, the Trump administration aims to create a more resilient framework that can swiftly address future pandemics without compromising public health.

The full episode of Steel News With Ann Vandersteel is available on OBBM Network TV.